Linagliptin vs Saxagliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Linagliptin · Tradjenta

Marketed by Boehringer Ingelheim and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00602472 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 1,058 participants, and its primary endpoint was met: adjusted HbA1c change was −0.72% with linagliptin versus −0.10% with placebo (p<0.0001). The evidence is considered moderate because HbA1c is a surrogate measure rather than a hard clinical endpoint.

Reported efficacy

The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years (met)

Result source: NCT01243424

Saxagliptin · Onglyza

Rights held by AstraZeneca and partners; US product discontinued

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT00121667 · Phase 3 · completed

Large randomized, double-blind, placebo-controlled phase 3 trial (743 treated participants across three saxagliptin doses and one placebo arm, all on background metformin). The primary endpoint was change from baseline in hemoglobin A1c at Week 24, an accepted hard glycemic measure for type 2 diabetes, and every saxagliptin dose showed a statistically significant improvement versus placebo (adjusted differences of -0.73, -0.83, and -0.72 percentage points, each p<0.0001). Because the trial was adequately powered, double-blind, and placebo-controlled, and the primary comparison was met, this is strong evidence for saxagliptin's efficacy.

Next expected readout: February 2027 · NCT02969798 (registry estimate)

Reported efficacy

Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07) (met)

Result source: NCT00121667

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLinagliptinSaxagliptin
HbA1c, change-0.6% vs 0.1%−0.6 vs placebo5 mg · wk 24 · n 618NCT00954447
129 other results
  • -0.7% vs -0.1% wk 24 · n 778 · Phase 3 · primary NCT00602472
  • -0.5% vs 0.1% wk 24 · n 513 · Phase 3 · primary NCT00601250
  • -0.6% vs -0.0% 5 mg · wk 24 · n 161 · Phase 3 · primary NCT01792518
  • -0.7% vs -0.2% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 24 · n 203 · Phase 3 · primary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 24 · n 179 · Phase 3 · primary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 24 · n 93 · Phase 3 · primary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 24 · n 160 · Phase 3 · primary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · primary NCT01087502
  • -1.1% vs -0.6% wk 24 · n 252 · Phase 3 · primary NCT00641043
  • -0.4% vs 0.3% wk 24 · n 333 · Phase 3 · primary NCT00621140
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -0.6% vs -0.2% wk 24 · n 100 · Phase 3 · primary NCT02897349
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · primary NCT01183013
  • 0.3% vs -0.2% 5 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.3% vs -1.6% 5 mg QD · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -1.3% vs -1.7% 5 mg QD · wk 24 · n 125 · Phase 3 · primary NCT01708902
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · primary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · primary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · primary NCT01183013
  • -2.1% vs -1.6% 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · primary NCT01708902
  • -2.3% vs -1.6% 2.5 mg / 1000 mg BID · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -2.2% vs -1.7% 2.5 mg / 500 mg BID · wk 24 · n 135 · Phase 3 · primary NCT01708902
  • -2.4% vs -1.7% 2.5 mg / 1000 mg BID · wk 24 · n 128 · Phase 3 · primary NCT01708902
  • -0.5% vs 0.1% 5 mg · wk 52 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0.1% 5 mg · wk 40 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 32 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 18 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 12 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0% 5 mg · wk 6 · n 618 · Phase 3 · secondary NCT00954447
  • -0.8% vs -0.1% wk 18 · n 778 · Phase 3 · secondary NCT00602472
  • -0.7% vs -0.2% 5 mg · wk 24 · n 168 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.2% 5 mg once daily · wk 24 · n 182 · Phase 3 · secondary NCT01215097
  • -0.7% vs -0.2% 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6% vs -0.1% 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.9% vs -0.4% 5 mg tablet · wk 18 · n 179 · Phase 3 · secondary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 18 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 18 · n 160 · Phase 3 · secondary NCT01084005
  • -0.6% vs -0.1% 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 12 · n 179 · Phase 3 · secondary NCT00996658
  • -0.7% vs -0.2% 5 mg · wk 12 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs -0.0% 5 mg · wk 12 · n 160 · Phase 3 · secondary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.5% vs -0.0% 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.6% vs -0.2% 5 mg tablet · wk 6 · n 179 · Phase 3 · secondary NCT00996658
  • -0.5% vs 0.1% wk 18 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.1% 5 mg · wk 6 · n 160 · Phase 3 · secondary NCT01084005
  • -1.1% vs -0.6% wk 18 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 18 · n 333 · Phase 3 · secondary NCT00621140
  • -0.8% vs -0.1% wk 12 · n 778 · Phase 3 · secondary NCT00602472
  • -0.5% vs 0.1% wk 12 · n 513 · Phase 3 · secondary NCT00601250
  • -0.8% vs -0.3% wk 12 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 12 · n 333 · Phase 3 · secondary NCT00621140
  • -0.7% vs -0.2% wk 6 · n 778 · Phase 3 · secondary NCT00602472
  • -0.4% vs 0.1% wk 6 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.0% wk 6 · n 252 · Phase 3 · secondary NCT00641043
  • -0.4% vs 0.1% wk 6 · n 333 · Phase 3 · secondary NCT00621140
  • -0.6% vs -0.2% 5 mg · wk 6 · n 93 · Phase 3 · secondary NCT01194830
  • -0.5% vs 0.1% 5 mg · wk 26 · n 5 · Phase 3 · secondary NCT03429543
  • 0.1% vs 0.1% wk 432 · n 2951 · Phase 3 · secondary NCT01243424
  • -0.4% vs -0.3% 5 mg · wk 52 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 46 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 40 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.4% 5 mg · wk 34 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 28 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 24 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.5% 5 mg · wk 20 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.6% 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.3% 5 mg · wk 16 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.4% 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.1% 5 mg · wk 8 · n 113 · Phase 3 · secondary NCT01087502
  • -0.2% vs -0.2% 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.3% vs -0.1% 5 mg · wk 4 · n 113 · Phase 3 · secondary NCT01087502
  • -0.9% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.7% 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.6% 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.6% 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.6% 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -0.7% vs -0.4% 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -0.9% vs -0.4% 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.0% vs -0.4% 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4% vs -0.2% 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.2% 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.2% 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 111 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 66 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 66 · n 111 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 111 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 78 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 78 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -1.0% vs -0.4% 5 mg · wk 24 · n 149 · Phase 4 · primary NCT02240680
  • -0.5% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · primary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · primary NCT01012037
  • -1.0% vs -1.0% 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · primary NCT01438814
  • -0.6% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 5 mg once daily · wk 6 · n 221 · Phase 2 · secondary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 2.5 mg twice daily · wk 6 · n 214 · Phase 2 · secondary NCT01012037
  • -0.8% vs -0.8% 5 mg once daily + metformin once daily · wk 8 · n 298 · Phase 4 · secondary NCT01438814
  • -0.3% vs -0.3% 5 mg once daily + metformin once daily · wk 2 · n 298 · Phase 4 · secondary NCT01438814
  • 7.6% vs 8% wk 12 · n 128 · Phase 4 · secondary NCT02004366
  • 6.6% vs 8% wk 12 · n 92 · Phase 4 · secondary NCT02004366
  • 7% vs 8% wk 12 · n 93 · Phase 4 · secondary NCT02004366
  • 8.6% vs 8% wk 12 · n 39 · Phase 4 · secondary NCT02004366
-0.7% vs -0.3%−0.4 vs placebo5 mg · wk 24 · n 300NCT00757588
19 other results
  • 7.1% vs 7.5% 5 mg · wk 24 · n 275 · Phase 3 · primary NCT00661362
  • -0.5% vs -0.2% 5 mg · wk 24 · n 139 · Phase 3 · primary NCT01619059
  • 0.1% vs 0.5% wk 26 · n 82 · Phase 3 · primary NCT03199053
  • -0.8% vs -0.1% wk 24 · n 158 · Phase 3 · primary NCT01646320
  • -0.7% vs -0.1% wk 24 · n 127 · Phase 3 · primary NCT01128153
  • -0.7% vs 0.6% wk 16 · n 4 · Phase 3 · primary NCT01204775
  • -1% vs 0.9% wk 16 · n 4 · Phase 3 · primary NCT01434186
  • -1.4% vs -1.0% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 218 · Phase 3 · primary NCT02419612
  • -1.4% vs -1.1% wk 26 · n 224 · Phase 3 · primary NCT02284893
  • -1.7% vs -1.5% wk 24 · n 319 · Phase 3 · primary NCT02551874
  • -1.0% vs -0.7% wk 24 · n 290 · Phase 3 · primary NCT02681094
  • -0.2% vs -0.7% 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • 0.1% vs -0.7% 2.5 mg · wk 26 · n 24 · Phase 3 · secondary NCT03199053
  • -0.8% vs -1.0% 10mg · wk 52 · n 311 · Phase 4 · primary NCT02471404
  • -1.2% vs -1.0% 5mg and 10mg · wk 52 · n 312 · Phase 4 · primary NCT02471404
  • -0.8% vs -0.8% wk 24 · n 238 · Phase 4 · primary NCT02243176
  • -0.8% vs -0.8% wk 24 · n 219 · Phase 4 · primary NCT02243176
  • -0.5% vs -0.4% wk 24 · n 146 · Phase 4 · primary NCT01006590
  • -0.4% vs -0.6% 5 mg · wk 52 · n 353 · Phase 4 · secondary NCT01006603
Body weight, change (kg)1.4 vs -0.0+1.5 vs placebo5 mg · wk 26 · n 49NCT03429543
4 other results
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 2.7 vs -0.0 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • -0.4 vs -1.1 5 mg once daily + metformin once daily · wk 14 · n 287 · Phase 4 · secondary NCT01438814
-1.9 vs -0.4−1.5 vs placebowk 24 · n 158NCT01646320
7 other results
  • -3.1 vs 0.9 dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 224 · Phase 3 · secondary NCT02419612
  • -1.9 vs -0.5 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -1.5 vs 2.1 wk 24 · n 319 · Phase 3 · secondary NCT02551874
  • -2.0 vs -0.4 wk 24 · n 290 · Phase 3 · secondary NCT02681094
  • -3.5 vs 1.8 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -3.1 vs 1.8 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.4 vs -2.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176
HbA1c below 7%26.9% vs 24.5%+2.4 vs placebo5 mg · wk 26 · n 52NCT03429543
7 other results
  • 13.9% vs 8.2% wk 24 · n 101 · Phase 3 · secondary NCT02897349
  • 16.7% vs 24.5% 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • 43.6% vs 50% 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 72.1% vs 50% 2.5 mg / 500 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 77.1% vs 50% 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 33% vs 10% 5 mg once daily · wk 12 · n 215 · Phase 2 · secondary NCT01012037
  • 34% vs 10% 2.5 mg twice daily · wk 12 · n 206 · Phase 2 · secondary NCT01012037
44.4% vs 16.6%+27.8 vs placebo10 mg · wk 24 · n 180NCT00121667
15 other results
  • 41.1% vs 23.9% 10 mg · wk 24 · n 95 · Phase 3 · secondary NCT00121641
  • 43.5% vs 16.6% 5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 37.9% vs 23.9% 5 mg · wk 24 · n 103 · Phase 3 · secondary NCT00121641
  • 22.1% vs 13.3% 5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00918879
  • 45.8% vs 28.8% 5 mg · wk 24 · n 277 · Phase 3 · secondary NCT00698932
  • 37.1% vs 16.6% 2.5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 35% vs 23.9% 2.5 mg · wk 24 · n 100 · Phase 3 · secondary NCT00121641
  • 37.5% vs 24.2% 2.5 mg · wk 12 · n 73 · Phase 3 · secondary NCT00885378
  • 21.3% vs 10% wk 26 · n 61 · Phase 3 · secondary NCT03199053
  • 36.7% vs 13.3% wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • 44.3% vs 34.3% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 227 · Phase 3 · secondary NCT02419612
  • 21.4% vs 11.7% dapagliflozin 10 mg, saxagliptin 5 mg · wk 156 · n 227 · Phase 3 · secondary NCT02419612
  • 37.3% vs 25.1% wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • 37.2% vs 26.1% wk 18 · n 137 · Phase 3 · secondary NCT00960076
  • 38.3% vs 41.5% wk 24 · n 230 · Phase 4 · secondary NCT02243176
Fasting plasma glucose, change-0.1 vs 0.0−0.2 vs placebo5 mg · wk 52 · n 614NCT00954447
95 other results
  • -0.4 vs -0.2 5 mg · wk 40 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs -0.1 5 mg · wk 32 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.3 5 mg · wk 24 · n 614 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.2 5 mg · wk 6 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.5 wk 24 · n 739 · Phase 3 · secondary NCT00602472
  • -0.5 vs 0.1 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6 vs -0.1 5 mg once daily · wk 24 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs 0 5 mg · wk 24 · n 606 · Phase 3 · secondary NCT00954447
  • -0.2 vs 0.1 5 mg · wk 18 · n 606 · Phase 3 · secondary NCT00954447
  • -0.6 vs 0.0 5 mg tablet · wk 24 · n 175 · Phase 3 · secondary NCT00996658
  • -0.6 vs 0.6 wk 24 · n 495 · Phase 3 · secondary NCT00601250
  • -0.3 vs 0.4 wk 18 · n 739 · Phase 3 · secondary NCT00602472
  • -0.6 vs 0.6 wk 18 · n 495 · Phase 3 · secondary NCT00601250
  • -0.5 vs 0.3 wk 12 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.2 wk 12 · n 495 · Phase 3 · secondary NCT00601250
  • -0.6 vs 0.3 wk 6 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.3 wk 6 · n 495 · Phase 3 · secondary NCT00601250
  • -1.3 vs -0.6 5 mg · wk 24 · n 95 · Phase 3 · secondary NCT01194830
  • -0.6 vs 0.6 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7 vs -0.1 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.5 vs -0.1 5 mg tablet · wk 18 · n 175 · Phase 3 · secondary NCT00996658
  • -0.7 vs 0.5 5 mg · wk 18 · n 145 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.8 vs -0.3 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs -0.0 5 mg · wk 12 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.2 5 mg tablet · wk 12 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.4 5 mg · wk 12 · n 148 · Phase 3 · secondary NCT01084005
  • -0.7 vs -0.0 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.9 vs 0.3 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.2 vs 0.7 5 mg tablet · wk 6 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.3 5 mg · wk 6 · n 153 · Phase 3 · secondary NCT01084005
  • -1.8 vs 0.3 25 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.0 wk 24 · n 243 · Phase 3 · secondary NCT00641043
  • -0.5 vs 0.8 wk 24 · n 318 · Phase 3 · secondary NCT00621140
  • -1.8 vs -1.1 wk 18 · n 243 · Phase 3 · secondary NCT00641043
  • -0.4 vs 0.7 wk 18 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -1.1 wk 12 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.6 wk 12 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -0.9 wk 6 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.4 wk 6 · n 318 · Phase 3 · secondary NCT00621140
  • 0.2 vs -0.2 5 mg · wk 52 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.1 5 mg · wk 46 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.0 5 mg · wk 40 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.6 5 mg · wk 34 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -1.6 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • 0 vs -1.4 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5 vs -0.5 5 mg · wk 28 · n 112 · Phase 3 · secondary NCT01087502
  • -0.8 vs -1.7 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.3 vs -1.2 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.7 vs -0.5 5 mg · wk 24 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs -0.5 5 mg · wk 20 · n 112 · Phase 3 · secondary NCT01087502
  • -0.4 vs -1.1 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.4 vs -1.2 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • 0.0 vs 0.5 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs 0.3 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.6 vs 0.5 5 mg · wk 8 · n 112 · Phase 3 · secondary NCT01087502
  • -0.2 vs -0.9 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.6 vs 0.5 5 mg · wk 4 · n 112 · Phase 3 · secondary NCT01087502
  • -1.1 vs -1.6 5 mg + 15 mg · wk 30 · n 119 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.6 5 mg + 30 mg · wk 30 · n 123 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.6 5 mg + 45 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1 vs -1.4 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.4 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.4 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.9 vs -1.2 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -1.1 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -1 vs -1.2 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.2 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -1.2 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -0.9 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -0.9 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -0.9 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4 vs -0.3 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.3 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -0.5 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -2.2 vs -1.7 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · secondary NCT01708902
  • -2.6 vs -1.7 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 2 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 2 · n 171 · Phase 3 · secondary NCT00915772
  • -1.2 vs -0.2 5 mg once daily · wk 12 · n 213 · Phase 2 · secondary NCT01012037
  • -0.9 vs -0.2 2.5 mg twice daily · wk 12 · n 203 · Phase 2 · secondary NCT01012037
  • -1.4 vs -1.5 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · secondary NCT01438814
-0.6 vs -0.3−0.2 vs placebo5 mg · wk 24 · n 300NCT00757588
11 other results
  • -0.5 vs -0.3 5 mg · wk 24 · n 139 · Phase 3 · secondary NCT01619059
  • 0.1 vs 0.2 wk 26 · n 80 · Phase 3 · secondary NCT03199053
  • -1.8 vs -0.3 wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • -0.3 vs 0.1 wk 24 · n 121 · Phase 3 · secondary NCT01128153
  • -1.8 vs -0.6 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -2.4 vs -1.0 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • -0.6 vs -1.0 2.5 mg · wk 26 · n 23 · Phase 3 · secondary NCT03199053
  • -1.6 vs -1.5 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -0.7 vs -1.3 5 mg · wk 52 · n 344 · Phase 4 · secondary NCT01006603
  • -2.1 vs -1.5 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.0 vs -1.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176
3-point MACE (% with event)20.7% vs 21.2%vs Glimepiridewk 432 · n 3023NCT01243424
2 other results
  • 11.8% vs 12% wk 432 · n 3023 · Phase 3 · secondary NCT01243424
  • 12.4% vs 12.1% n 3494 · Phase 4 · primary NCT01897532
7.4% vs 7.4%±0 vs placebon 8280NCT01107886

HbA1c, change

Linagliptin
-0.6% vs 0.1%−0.6 vs placebo5 mg · wk 24 · n 618NCT00954447
129 other results
  • -0.7% vs -0.1% wk 24 · n 778 · Phase 3 · primary NCT00602472
  • -0.5% vs 0.1% wk 24 · n 513 · Phase 3 · primary NCT00601250
  • -0.6% vs -0.0% 5 mg · wk 24 · n 161 · Phase 3 · primary NCT01792518
  • -0.7% vs -0.2% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 24 · n 203 · Phase 3 · primary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 24 · n 179 · Phase 3 · primary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 24 · n 93 · Phase 3 · primary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 24 · n 160 · Phase 3 · primary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · primary NCT01087502
  • -1.1% vs -0.6% wk 24 · n 252 · Phase 3 · primary NCT00641043
  • -0.4% vs 0.3% wk 24 · n 333 · Phase 3 · primary NCT00621140
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -0.6% vs -0.2% wk 24 · n 100 · Phase 3 · primary NCT02897349
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · primary NCT01183013
  • 0.3% vs -0.2% 5 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.3% vs -1.6% 5 mg QD · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -1.3% vs -1.7% 5 mg QD · wk 24 · n 125 · Phase 3 · primary NCT01708902
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · primary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · primary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · primary NCT01183013
  • -2.1% vs -1.6% 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · primary NCT01708902
  • -2.3% vs -1.6% 2.5 mg / 1000 mg BID · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -2.2% vs -1.7% 2.5 mg / 500 mg BID · wk 24 · n 135 · Phase 3 · primary NCT01708902
  • -2.4% vs -1.7% 2.5 mg / 1000 mg BID · wk 24 · n 128 · Phase 3 · primary NCT01708902
  • -0.5% vs 0.1% 5 mg · wk 52 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0.1% 5 mg · wk 40 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 32 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 18 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 12 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0% 5 mg · wk 6 · n 618 · Phase 3 · secondary NCT00954447
  • -0.8% vs -0.1% wk 18 · n 778 · Phase 3 · secondary NCT00602472
  • -0.7% vs -0.2% 5 mg · wk 24 · n 168 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.2% 5 mg once daily · wk 24 · n 182 · Phase 3 · secondary NCT01215097
  • -0.7% vs -0.2% 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6% vs -0.1% 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.9% vs -0.4% 5 mg tablet · wk 18 · n 179 · Phase 3 · secondary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 18 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 18 · n 160 · Phase 3 · secondary NCT01084005
  • -0.6% vs -0.1% 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 12 · n 179 · Phase 3 · secondary NCT00996658
  • -0.7% vs -0.2% 5 mg · wk 12 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs -0.0% 5 mg · wk 12 · n 160 · Phase 3 · secondary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.5% vs -0.0% 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.6% vs -0.2% 5 mg tablet · wk 6 · n 179 · Phase 3 · secondary NCT00996658
  • -0.5% vs 0.1% wk 18 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.1% 5 mg · wk 6 · n 160 · Phase 3 · secondary NCT01084005
  • -1.1% vs -0.6% wk 18 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 18 · n 333 · Phase 3 · secondary NCT00621140
  • -0.8% vs -0.1% wk 12 · n 778 · Phase 3 · secondary NCT00602472
  • -0.5% vs 0.1% wk 12 · n 513 · Phase 3 · secondary NCT00601250
  • -0.8% vs -0.3% wk 12 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 12 · n 333 · Phase 3 · secondary NCT00621140
  • -0.7% vs -0.2% wk 6 · n 778 · Phase 3 · secondary NCT00602472
  • -0.4% vs 0.1% wk 6 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.0% wk 6 · n 252 · Phase 3 · secondary NCT00641043
  • -0.4% vs 0.1% wk 6 · n 333 · Phase 3 · secondary NCT00621140
  • -0.6% vs -0.2% 5 mg · wk 6 · n 93 · Phase 3 · secondary NCT01194830
  • -0.5% vs 0.1% 5 mg · wk 26 · n 5 · Phase 3 · secondary NCT03429543
  • 0.1% vs 0.1% wk 432 · n 2951 · Phase 3 · secondary NCT01243424
  • -0.4% vs -0.3% 5 mg · wk 52 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 46 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 40 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.4% 5 mg · wk 34 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 28 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 24 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.5% 5 mg · wk 20 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.6% 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.3% 5 mg · wk 16 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.4% 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.1% 5 mg · wk 8 · n 113 · Phase 3 · secondary NCT01087502
  • -0.2% vs -0.2% 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.3% vs -0.1% 5 mg · wk 4 · n 113 · Phase 3 · secondary NCT01087502
  • -0.9% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.7% 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.6% 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.6% 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.6% 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -0.7% vs -0.4% 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -0.9% vs -0.4% 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.0% vs -0.4% 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4% vs -0.2% 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.2% 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.2% 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 111 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 66 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 66 · n 111 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 111 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 78 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 78 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -1.0% vs -0.4% 5 mg · wk 24 · n 149 · Phase 4 · primary NCT02240680
  • -0.5% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · primary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · primary NCT01012037
  • -1.0% vs -1.0% 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · primary NCT01438814
  • -0.6% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 5 mg once daily · wk 6 · n 221 · Phase 2 · secondary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 2.5 mg twice daily · wk 6 · n 214 · Phase 2 · secondary NCT01012037
  • -0.8% vs -0.8% 5 mg once daily + metformin once daily · wk 8 · n 298 · Phase 4 · secondary NCT01438814
  • -0.3% vs -0.3% 5 mg once daily + metformin once daily · wk 2 · n 298 · Phase 4 · secondary NCT01438814
  • 7.6% vs 8% wk 12 · n 128 · Phase 4 · secondary NCT02004366
  • 6.6% vs 8% wk 12 · n 92 · Phase 4 · secondary NCT02004366
  • 7% vs 8% wk 12 · n 93 · Phase 4 · secondary NCT02004366
  • 8.6% vs 8% wk 12 · n 39 · Phase 4 · secondary NCT02004366
Saxagliptin
-0.7% vs -0.3%−0.4 vs placebo5 mg · wk 24 · n 300NCT00757588
19 other results
  • 7.1% vs 7.5% 5 mg · wk 24 · n 275 · Phase 3 · primary NCT00661362
  • -0.5% vs -0.2% 5 mg · wk 24 · n 139 · Phase 3 · primary NCT01619059
  • 0.1% vs 0.5% wk 26 · n 82 · Phase 3 · primary NCT03199053
  • -0.8% vs -0.1% wk 24 · n 158 · Phase 3 · primary NCT01646320
  • -0.7% vs -0.1% wk 24 · n 127 · Phase 3 · primary NCT01128153
  • -0.7% vs 0.6% wk 16 · n 4 · Phase 3 · primary NCT01204775
  • -1% vs 0.9% wk 16 · n 4 · Phase 3 · primary NCT01434186
  • -1.4% vs -1.0% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 218 · Phase 3 · primary NCT02419612
  • -1.4% vs -1.1% wk 26 · n 224 · Phase 3 · primary NCT02284893
  • -1.7% vs -1.5% wk 24 · n 319 · Phase 3 · primary NCT02551874
  • -1.0% vs -0.7% wk 24 · n 290 · Phase 3 · primary NCT02681094
  • -0.2% vs -0.7% 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • 0.1% vs -0.7% 2.5 mg · wk 26 · n 24 · Phase 3 · secondary NCT03199053
  • -0.8% vs -1.0% 10mg · wk 52 · n 311 · Phase 4 · primary NCT02471404
  • -1.2% vs -1.0% 5mg and 10mg · wk 52 · n 312 · Phase 4 · primary NCT02471404
  • -0.8% vs -0.8% wk 24 · n 238 · Phase 4 · primary NCT02243176
  • -0.8% vs -0.8% wk 24 · n 219 · Phase 4 · primary NCT02243176
  • -0.5% vs -0.4% wk 24 · n 146 · Phase 4 · primary NCT01006590
  • -0.4% vs -0.6% 5 mg · wk 52 · n 353 · Phase 4 · secondary NCT01006603

Body weight, change (kg)

Linagliptin
1.4 vs -0.0+1.5 vs placebo5 mg · wk 26 · n 49NCT03429543
4 other results
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 2.7 vs -0.0 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • -0.4 vs -1.1 5 mg once daily + metformin once daily · wk 14 · n 287 · Phase 4 · secondary NCT01438814
Saxagliptin
-1.9 vs -0.4−1.5 vs placebowk 24 · n 158NCT01646320
7 other results
  • -3.1 vs 0.9 dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 224 · Phase 3 · secondary NCT02419612
  • -1.9 vs -0.5 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -1.5 vs 2.1 wk 24 · n 319 · Phase 3 · secondary NCT02551874
  • -2.0 vs -0.4 wk 24 · n 290 · Phase 3 · secondary NCT02681094
  • -3.5 vs 1.8 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -3.1 vs 1.8 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.4 vs -2.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176

HbA1c below 7%

Linagliptin
26.9% vs 24.5%+2.4 vs placebo5 mg · wk 26 · n 52NCT03429543
7 other results
  • 13.9% vs 8.2% wk 24 · n 101 · Phase 3 · secondary NCT02897349
  • 16.7% vs 24.5% 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • 43.6% vs 50% 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 72.1% vs 50% 2.5 mg / 500 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 77.1% vs 50% 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 33% vs 10% 5 mg once daily · wk 12 · n 215 · Phase 2 · secondary NCT01012037
  • 34% vs 10% 2.5 mg twice daily · wk 12 · n 206 · Phase 2 · secondary NCT01012037
Saxagliptin
44.4% vs 16.6%+27.8 vs placebo10 mg · wk 24 · n 180NCT00121667
15 other results
  • 41.1% vs 23.9% 10 mg · wk 24 · n 95 · Phase 3 · secondary NCT00121641
  • 43.5% vs 16.6% 5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 37.9% vs 23.9% 5 mg · wk 24 · n 103 · Phase 3 · secondary NCT00121641
  • 22.1% vs 13.3% 5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00918879
  • 45.8% vs 28.8% 5 mg · wk 24 · n 277 · Phase 3 · secondary NCT00698932
  • 37.1% vs 16.6% 2.5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 35% vs 23.9% 2.5 mg · wk 24 · n 100 · Phase 3 · secondary NCT00121641
  • 37.5% vs 24.2% 2.5 mg · wk 12 · n 73 · Phase 3 · secondary NCT00885378
  • 21.3% vs 10% wk 26 · n 61 · Phase 3 · secondary NCT03199053
  • 36.7% vs 13.3% wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • 44.3% vs 34.3% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 227 · Phase 3 · secondary NCT02419612
  • 21.4% vs 11.7% dapagliflozin 10 mg, saxagliptin 5 mg · wk 156 · n 227 · Phase 3 · secondary NCT02419612
  • 37.3% vs 25.1% wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • 37.2% vs 26.1% wk 18 · n 137 · Phase 3 · secondary NCT00960076
  • 38.3% vs 41.5% wk 24 · n 230 · Phase 4 · secondary NCT02243176

Fasting plasma glucose, change

Linagliptin
-0.1 vs 0.0−0.2 vs placebo5 mg · wk 52 · n 614NCT00954447
95 other results
  • -0.4 vs -0.2 5 mg · wk 40 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs -0.1 5 mg · wk 32 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.3 5 mg · wk 24 · n 614 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.2 5 mg · wk 6 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.5 wk 24 · n 739 · Phase 3 · secondary NCT00602472
  • -0.5 vs 0.1 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6 vs -0.1 5 mg once daily · wk 24 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs 0 5 mg · wk 24 · n 606 · Phase 3 · secondary NCT00954447
  • -0.2 vs 0.1 5 mg · wk 18 · n 606 · Phase 3 · secondary NCT00954447
  • -0.6 vs 0.0 5 mg tablet · wk 24 · n 175 · Phase 3 · secondary NCT00996658
  • -0.6 vs 0.6 wk 24 · n 495 · Phase 3 · secondary NCT00601250
  • -0.3 vs 0.4 wk 18 · n 739 · Phase 3 · secondary NCT00602472
  • -0.6 vs 0.6 wk 18 · n 495 · Phase 3 · secondary NCT00601250
  • -0.5 vs 0.3 wk 12 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.2 wk 12 · n 495 · Phase 3 · secondary NCT00601250
  • -0.6 vs 0.3 wk 6 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.3 wk 6 · n 495 · Phase 3 · secondary NCT00601250
  • -1.3 vs -0.6 5 mg · wk 24 · n 95 · Phase 3 · secondary NCT01194830
  • -0.6 vs 0.6 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7 vs -0.1 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.5 vs -0.1 5 mg tablet · wk 18 · n 175 · Phase 3 · secondary NCT00996658
  • -0.7 vs 0.5 5 mg · wk 18 · n 145 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.8 vs -0.3 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs -0.0 5 mg · wk 12 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.2 5 mg tablet · wk 12 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.4 5 mg · wk 12 · n 148 · Phase 3 · secondary NCT01084005
  • -0.7 vs -0.0 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.9 vs 0.3 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.2 vs 0.7 5 mg tablet · wk 6 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.3 5 mg · wk 6 · n 153 · Phase 3 · secondary NCT01084005
  • -1.8 vs 0.3 25 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.0 wk 24 · n 243 · Phase 3 · secondary NCT00641043
  • -0.5 vs 0.8 wk 24 · n 318 · Phase 3 · secondary NCT00621140
  • -1.8 vs -1.1 wk 18 · n 243 · Phase 3 · secondary NCT00641043
  • -0.4 vs 0.7 wk 18 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -1.1 wk 12 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.6 wk 12 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -0.9 wk 6 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.4 wk 6 · n 318 · Phase 3 · secondary NCT00621140
  • 0.2 vs -0.2 5 mg · wk 52 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.1 5 mg · wk 46 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.0 5 mg · wk 40 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.6 5 mg · wk 34 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -1.6 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • 0 vs -1.4 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5 vs -0.5 5 mg · wk 28 · n 112 · Phase 3 · secondary NCT01087502
  • -0.8 vs -1.7 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.3 vs -1.2 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.7 vs -0.5 5 mg · wk 24 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs -0.5 5 mg · wk 20 · n 112 · Phase 3 · secondary NCT01087502
  • -0.4 vs -1.1 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.4 vs -1.2 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • 0.0 vs 0.5 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs 0.3 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.6 vs 0.5 5 mg · wk 8 · n 112 · Phase 3 · secondary NCT01087502
  • -0.2 vs -0.9 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.6 vs 0.5 5 mg · wk 4 · n 112 · Phase 3 · secondary NCT01087502
  • -1.1 vs -1.6 5 mg + 15 mg · wk 30 · n 119 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.6 5 mg + 30 mg · wk 30 · n 123 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.6 5 mg + 45 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1 vs -1.4 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.4 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.4 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.9 vs -1.2 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -1.1 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -1 vs -1.2 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.2 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -1.2 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -0.9 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -0.9 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -0.9 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4 vs -0.3 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.3 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -0.5 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -2.2 vs -1.7 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · secondary NCT01708902
  • -2.6 vs -1.7 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 2 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 2 · n 171 · Phase 3 · secondary NCT00915772
  • -1.2 vs -0.2 5 mg once daily · wk 12 · n 213 · Phase 2 · secondary NCT01012037
  • -0.9 vs -0.2 2.5 mg twice daily · wk 12 · n 203 · Phase 2 · secondary NCT01012037
  • -1.4 vs -1.5 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · secondary NCT01438814
Saxagliptin
-0.6 vs -0.3−0.2 vs placebo5 mg · wk 24 · n 300NCT00757588
11 other results
  • -0.5 vs -0.3 5 mg · wk 24 · n 139 · Phase 3 · secondary NCT01619059
  • 0.1 vs 0.2 wk 26 · n 80 · Phase 3 · secondary NCT03199053
  • -1.8 vs -0.3 wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • -0.3 vs 0.1 wk 24 · n 121 · Phase 3 · secondary NCT01128153
  • -1.8 vs -0.6 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -2.4 vs -1.0 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • -0.6 vs -1.0 2.5 mg · wk 26 · n 23 · Phase 3 · secondary NCT03199053
  • -1.6 vs -1.5 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -0.7 vs -1.3 5 mg · wk 52 · n 344 · Phase 4 · secondary NCT01006603
  • -2.1 vs -1.5 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.0 vs -1.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176

3-point MACE (% with event)

Linagliptin
20.7% vs 21.2%vs Glimepiridewk 432 · n 3023NCT01243424
2 other results
  • 11.8% vs 12% wk 432 · n 3023 · Phase 3 · secondary NCT01243424
  • 12.4% vs 12.1% n 3494 · Phase 4 · primary NCT01897532
Saxagliptin
7.4% vs 7.4%±0 vs placebon 8280NCT01107886
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety

Coverage. Linagliptin: 13 of 13 rows · Saxagliptin: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLinagliptin
Rows use multiple source trials
Saxagliptin
Rows use multiple source trials
Fasting Plasma Glucose
absolute change · mmol/L
No placebo or comparator arm
-1.68 mmol/L @ 24wk*5 mga,b
NCT01512979 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -30.2 mg/dL as posted
show 3 more doses
-1.67 mmol/L @ 24wk*5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -30.1 mg/dL as posted
-2.61 mmol/L @ 24wk*5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -47.1 mg/dL as posted
-2.61 mmol/L @ 24wk*5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -47.1 mg/dL as posted
-0.55 mmol/L @ 24wkb
NCT01608724 · Phase 4 · registry result, not featured evidence
1 other source trial
-0.62 mmol/L @ 24wk*
NCT02104804 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -11.23 mg/dL as posted
Fasting Plasma Glucose Change mg/dL
absolute change · mg
-11.3 vs 0.2 placebo mg @ 24wk5 mgc,b,d
NCT02240680 · Phase 4 · registry result, not featured evidence
1 other source trial
-5.5 vs 0.7 placebo mg @ 24wk
NCT02897349 · Phase 3 · registry result, not featured evidence
-27.53 vs -19.95 Dapagliflozin + Metformin mg @ 24wkc,b,d
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
Glycemic Rescue
responder rate · % of participants
7.1% (n=141) vs 2.1% (n=144) Metformin @ 24wk5 mg QDa,b,e
NCT01708902 · Phase 3 · registry result, not featured evidence
show 2 more doses
2.1% (n=141) vs 2.1% (n=144) Metformin @ 24wk2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.4% (n=142) vs 2.1% (n=144) Metformin @ 24wk2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
37% (n=227) vs 55.6% (n=216) Glimepiride @ 156wkdapagliflozin 10 mg, saxagliptin 5 mgb,e
NCT02419612 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-2.02% (n=113) @ 24wk5 mga,c,b
NCT01512979 · Phase 4 · registry result, not featured evidence
show 3 more doses
-2.01% (n=113) @ 24wk5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
-2.81% (n=132) @ 24wk5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
-2.81% (n=132) @ 24wk5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
-0.64% (n=229) @ 24wkc,b
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
HbA1c 7.0 or Less
event count · % of participants
21.7% (n=618) vs 9.1% (n=617) placebo @ 24wk*5 mgb,d
NCT00954447 · Phase 3 · registry result, not featured evidence · converted to % from 134 Participants as posted
30.7% (n=127) vs 9.4% (n=127) placebo @ 24wk*b,d
NCT01128153 · Phase 3 · registry result, not featured evidence · converted to % from 39 Participants as posted
HbA1c Less Than 7
absolute value · percentage points
22.1% (n=108) vs 11.8% (n=110) Glimepiride @ 52wk5 mgf,b,d
NCT01087502 · Phase 3 · registry result, not featured evidence
44.7% (n=356) vs 54.7% (n=353) Glimepiride @ 52wk5 mgf,b,d
NCT01006603 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7%
event count · % of participants
48% (n=196) vs 27.7% (n=94) placebo @ 24wk*5 mga,b,d
NCT01214239 · Phase 3 · registry result, not featured evidence · converted to % from 94 Patients as posted
show 1 more dose
45.5% (n=176) vs 25.8% (n=89) placebo @ 24wk*5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence · converted to % from 80 Patients as posted
42.8% (n=290) vs 21.8% (n=289) Dapagliflozin + Metformin @ 24wk*b,d
NCT02681094 · Phase 3 · registry result, not featured evidence · add on · converted to % from 124 Participants as posted
HbA1c Less Than 7%
responder rate · % of participants
No placebo or comparator arm
27.1% (n=70) @ 12wk5 mg QDa,f,b
NCT01708902 · Phase 3 · registry result, not featured evidence
show 1 more dose
58.8% (n=68) @ 12wk2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
45.6% (n=1210) @ 12wkf,b
NCT01608724 · Phase 4 · registry result, not featured evidence
PPG 2h Change mg/dL
absolute change · mmol/L
-2.71 vs 1.01 placebo mmol/L @ 24wk*b,g
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -48.86 mg/dL as posted
3 other source trials
-1.78 vs 0 placebo mmol/L @ 24wk*
NCT02897349 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -32.01 mg/dL as posted
-2.15 vs -2.04 placebo mmol/L @ 24wk*5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -38.74 mg/dL as posted
-1.86 vs 1.38 placebo mmol/L @ 24wk*
NCT00621140 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -33.51 mg/dL as posted
-4.08 vs -2.11 placebo mmol/L @ 24wk*b,g
NCT01646320 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -73.5 mg/dL as posted
2 other source trials
-2.06 vs -1.74 placebo mmol/L @ 24wk*5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -37.1 mg/dL as posted
-1.51 vs -0.23 placebo mmol/L @ 24wk*5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -27.2 mg/dL as posted
Dropout rate
7.3%h
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 57 more results
7.5%
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
4.3%
NCT01243424 · Phase 3
0%
NCT02467478 · Phase 4 · registry result, not featured evidence
15%5 mg per day
NCT02372630 · Phase 4 · registry result, not featured evidence
24%
NCT01897532 · Phase 4 · registry result, not featured evidence
5.3%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
0%Linagliptin In-hospital
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin on Discharge
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin+50%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
—Linagliptin+80%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
20%
NCT02350478 · Phase 4 · registry result, not featured evidence
0%
NCT01969084 · Phase 4 · registry result, not featured evidence
14%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
11.9%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
4.1%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
5.8%
NCT02897349 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
3.8%5 mg
NCT01792518 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT01708902 · Phase 3 · registry result, not featured evidence
9.9%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
11.6%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD, then 2.5 mg / Metformin after week 12
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
9.7%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
10.9%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
6.8%2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
22.2%5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
28.6%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
33.8%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
27.8%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
6.8%5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
9%5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
6.8%5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
11.3%5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
2.4%A-GI+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
3.7%Bigu+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
12.1%Glin+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
6.8%Glit+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
7.7%SU+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
24.5%5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
13.9%5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
17%linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
20.4%linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
9.9%5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
21.2%
NCT00740051 · Phase 3 · registry result, not featured evidence
5.8%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
5.4%
NCT00621140 · Phase 3 · registry result, not featured evidence
4.5%5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
7.2%2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
22.7%10 mgi
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
25.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
22.9%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
29.6%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
35.8%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
28.4%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%
NCT02024477 · Phase 4 · registry result, not featured evidence
10.5%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
4.5%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
5.7%
NCT02243176 · Phase 4 · registry result, not featured evidence
17.1%
NCT01608724 · Phase 4 · registry result, not featured evidence
2.4%
NCT01107886 · Phase 4 · registry result, not featured evidence
19.7%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
19%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
5.7%Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
7.5%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
8.6%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
12.6%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
8.2%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
25%
NCT01204775 · Phase 3 · registry result, not featured evidence
0%
NCT01434186 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
6.8%Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
7.5%Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
7.2%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
—
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
12.4%
NCT01128153 · Phase 3 · registry result, not featured evidence
5.8%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
61.4%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
5.6%5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
4.3%5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
11.8%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
50.6%
NCT00614939 · Phase 3 · registry result, not featured evidence
10.8%2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
15%5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
7.7%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
10.2%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
Discontinued due to AEs
2.9%h
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 57 more results
1.7%
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—
NCT01243424 · Phase 3
—
NCT02467478 · Phase 4 · registry result, not featured evidence
—5 mg per day
NCT02372630 · Phase 4 · registry result, not featured evidence
10.3%
NCT01897532 · Phase 4 · registry result, not featured evidence
4%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—Linagliptin In-hospital
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin on Discharge
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin+50%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
—Linagliptin+80%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
—
NCT02350478 · Phase 4 · registry result, not featured evidence
0%
NCT01969084 · Phase 4 · registry result, not featured evidence
1.3%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
1.3%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
0.9%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT02897349 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
2.2%5 mg
NCT01792518 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT01708902 · Phase 3 · registry result, not featured evidence
4.2%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
2%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD, then 2.5 mg / Metformin after week 12
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
6.9%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
4.8%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.4%2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
3.7%5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
7.9%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
7.5%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
4.5%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
3.4%5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
2%5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
1.5%5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
2.7%5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
1.2%A-GI+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
2.4%Bigu+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
9.1%Glin+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
0%Glit+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
4.9%SU+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
1.8%5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
4%5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
6.4%linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
5.8%linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
4.9%5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
2.6%
NCT00740051 · Phase 3 · registry result, not featured evidence
1.5%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
1.5%
NCT00621140 · Phase 3 · registry result, not featured evidence
1.3%5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
3.6%2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
2.8%10 mgi
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
3.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.6%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.1%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.8%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.9%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT02024477 · Phase 4 · registry result, not featured evidence
2.2%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
0.3%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
0.8%
NCT02243176 · Phase 4 · registry result, not featured evidence
2%
NCT01608724 · Phase 4 · registry result, not featured evidence
—
NCT01107886 · Phase 4 · registry result, not featured evidence
4.2%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
1.4%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
0.4%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
—
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
3.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
0.4%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
—
NCT01204775 · Phase 3 · registry result, not featured evidence
—
NCT01434186 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
1.7%Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
1.9%Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
0%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
—
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
0.8%
NCT01128153 · Phase 3 · registry result, not featured evidence
0.7%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
2.6%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
—5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
2%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
5.9%
NCT00614939 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
1.8%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
Serious AEs
3.2%h
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 57 more results
3.4%
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.4%5 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
46.4%
NCT01243424 · Phase 3
7.1%
NCT02467478 · Phase 4 · registry result, not featured evidence
0%5 mg per day
NCT02372630 · Phase 4 · registry result, not featured evidence
37%
NCT01897532 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
12.6%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
25%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
0.8%Linagliptin In-hospital
NCT02004366 · Phase 4 · registry result, not featured evidence
13%Linagliptin on Discharge
NCT02004366 · Phase 4 · registry result, not featured evidence
15.1%Linagliptin+50%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
23.1%Linagliptin+80%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
15%
NCT02350478 · Phase 4 · registry result, not featured evidence
5.3%
NCT01969084 · Phase 4 · registry result, not featured evidence
1.3%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
1.9%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
0.6%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
9.6%
NCT02897349 · Phase 3 · registry result, not featured evidence
5.2%25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
0.9%10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
9.3%5 mg
NCT01792518 · Phase 3 · registry result, not featured evidence
3.6%25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
4.5%10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
0%5 mg
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
1.4%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
1.4%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
3.2%5 mg QD, then 2.5 mg / Metformin after week 12
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.5%2.5 mg / 1000 mg
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.4%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.7%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
0.7%2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
6.7%5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
7.1%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
11.3%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
7.5%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
24.8%5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
0.5%5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
2%5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
2.2%5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
8.2%A-GI+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
9.8%Bigu+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
7.6%Glin+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
2.7%Glit+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
4.9%SU+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
0.9%5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
13.8%5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
8.2%linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
5.3%linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
8.6%5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
0.7%
NCT00740051 · Phase 3 · registry result, not featured evidence
3.1%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
3%
NCT00621140 · Phase 3 · registry result, not featured evidence
2.2%5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
4%2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
12.2%10 mgi
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
14.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
12%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.2%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
17%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.8%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.8%
NCT02024477 · Phase 4 · registry result, not featured evidence
12.5%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
7.1%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
2.1%
NCT02243176 · Phase 4 · registry result, not featured evidence
1.8%
NCT01608724 · Phase 4 · registry result, not featured evidence
25.5%
NCT01107886 · Phase 4 · registry result, not featured evidence
11.4%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
4.1%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
0%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
3.8%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
2.3%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
1.6%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
4.9%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
12.8%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
6.2%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
2.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
3.9%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01204775 · Phase 3 · registry result, not featured evidence
0%
NCT01434186 · Phase 3 · registry result, not featured evidence
5.1%5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
4.4%DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
—Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
4.6%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
1.1%
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT01128153 · Phase 3 · registry result, not featured evidence
0%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
12.6%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
0%5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
2.2%5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
8.2%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
27.1%
NCT00614939 · Phase 3 · registry result, not featured evidence
1.4%2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
5%5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
2.8%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
2.8%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
Most frequent reported AEs
h
hypoglycaemia 22.7% (placebo 14.8%)
upper respiratory tract infection 5.8% (placebo 9.1%)
hyperglycaemia 5.6% (placebo 8.7%)
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 50 more results
hyperglycaemia 5.2% (placebo 14.7%)
nasopharyngitis 5.2% (placebo 5.1%)
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 20.8% (placebo 12.1%)
headache 15.6% (placebo 15.5%)
blood ketone body increased 10.4% (placebo 3.4%)
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
nasopharyngitis 17.5%
hypertension 14.2%
hyperglycaemia 14%
NCT01243424 · Phase 3
hypoglycaemia 29.3% (placebo 28.8%)
hypertension 6.2% (placebo 6.7%)
hyperglycaemia 6% (placebo 6.9%)
NCT01897532 · Phase 4 · registry result, not featured evidence
5 mg
hypoglycaemia 33.8% (placebo 25.2%)
viral upper respiratory tract infection 7.3% (placebo 5.3%)
urinary tract infection 6.6% (placebo 6%)
NCT02240680 · Phase 4 · registry result, not featured evidence
5 mg
hypoglycaemia 38.5% (placebo 25.2%)
viral upper respiratory tract infection 21.2% (placebo 5.3%)
bronchitis 9.6% (placebo 2.6%)
NCT02240680 · Phase 4 · registry result, not featured evidence
infections 5.5%
renal 4.7%
surgical reintervention 4.7%
NCT02004366 · Phase 4 · registry result, not featured evidence
gastrointestinal 1.1%
musculoskeletal 1.1%
skin 1.1%
NCT02004366 · Phase 4 · registry result, not featured evidence
gastrointestinal 1.1%
hematologic 0%
infections 0%
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
gastrointestinal 0%
hematologic 0%
infections 0%
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
dorsal pain 5% (placebo 0%)
nausea 5% (placebo 4.3%)
toothache 5% (placebo 0%)
NCT02350478 · Phase 4 · registry result, not featured evidence
increased creatinine and bun, reduced gfr 5.3% (placebo 13.6%)
pneumonia 5.3% (placebo 0%)
cramping in the calf muscle during the graded exercise test 0% (placebo 4.5%)
NCT01969084 · Phase 4 · registry result, not featured evidence
5 mg
dyslipidaemia 14%
hyperglycaemia 12.7%
urinary tract infection 8.9%
NCT01512979 · Phase 4 · registry result, not featured evidence
5 mg + Metformin
dyslipidaemia 8.8%
headache 6.3%
urinary tract infection 6.3%
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
5 mg once daily + metformin once daily
diarrhoea 18%
abdominal pain 6.7%
nausea 6.7%
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
hypoglycaemia 17.3% (placebo 12.7%)
upper respiratory tract infection 13.5% (placebo 12.7%)
hyperuricaemia 5.8% (placebo 1%)
NCT02897349 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
viral upper respiratory tract infection 26.7% (placebo 22.2%)
blood ketone body increased 13.8% (placebo 10.2%)
back pain 6% (placebo 2.8%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
viral upper respiratory tract infection 15% (placebo 22.2%)
back pain 2.8% (placebo 2.8%)
contusion 2.8% (placebo 0.9%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
5 mg
hypoglycaemia 13.2% (placebo 5.6%)
nasopharyngitis 7.1% (placebo 5.6%)
upper respiratory tract infection 2.2% (placebo 5.1%)
NCT01792518 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
nasopharyngitis 3.6% (placebo 7.3%)
lipase increased 2.7% (placebo 5.5%)
urinary tract infection 2.7% (placebo 6.4%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
urinary tract infection 7.1% (placebo 6.4%)
nasopharyngitis 4.5% (placebo 7.3%)
lipase increased 3.6% (placebo 5.5%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
5 mg
diarrhoea 3%
hyperuricaemia 3%
dizziness 0%
NCT01708902 · Phase 3 · registry result, not featured evidence
5 mg QD
hyperglycaemia 16.9%
hyperuricaemia 5.6%
nasopharyngitis 5.6%
NCT01708902 · Phase 3 · registry result, not featured evidence
5 mg QD
hyperuricaemia 7.5%
hyperglycaemia 4.8%
upper respiratory tract infection 4.1%
NCT01708902 · Phase 3 · registry result, not featured evidence
5 mg QD, then 2.5 mg / Metformin after week 12
hyperuricaemia 19.4%
dizziness 6.5%
hyperglycaemia 6.5%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 1000 mg
hyperuricaemia 6.2%
hyperglycaemia 3.1%
diarrhoea 1.5%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 1000 mg BID
diarrhoea 5.6%
hyperuricaemia 5.6%
upper respiratory tract infection 5.6%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 1000 mg BID
diarrhoea 9.5%
hyperuricaemia 7.5%
upper respiratory tract infection 7.5%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 500 mg BID
upper respiratory tract infection 8.2%
hyperuricaemia 5.4%
diarrhoea 4.8%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
5 mg
hyperglycaemia 10.4%
nasopharyngitis 7.4%
hypertension 6.7%
NCT01183013 · Phase 3 · registry result, not featured evidence
5 mg + 15 mg / 5 mg + 30 mg
diarrhoea 7.9%
nasopharyngitis 7.1%
back pain 6.3%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
5 mg + 30 mg
oedema 9%
dizziness 6.8%
oedema peripheral 6.8%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
5 mg + 45 mg
oedema peripheral 11.3%
back pain 9%
urinary tract infection 5.3%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
5 mg
hypoglycaemia 59.3%
nasopharyngitis 18.6%
hyperglycaemia 17.7%
NCT01087502 · Phase 3 · registry result, not featured evidence
5 mg
hyperlipidaemia 5.5% (placebo 3%)
hyperglycaemia 2% (placebo 4%)
NCT01214239 · Phase 3 · registry result, not featured evidence
5 mg once daily
hyperglycaemia 4.9% (placebo 5%)
hyperlipidaemia 4.4% (placebo 4%)
diarrhoea 2.4% (placebo 1%)
NCT01215097 · Phase 3 · registry result, not featured evidence
5 mg tablet
anaemia 7.1% (placebo 6.7%)
hyperglycaemia 6% (placebo 7.9%)
hypoglycaemia 5.5% (placebo 4.5%)
NCT00996658 · Phase 3 · registry result, not featured evidence
nasopharyngitis 41.2%
back pain 5.9%
constipation 5.9%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 36.6%
bronchitis 11%
arthralgia 6.1%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 45.5%
pharyngitis 7.6%
constipation 4.5%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 33.8%
upper respiratory tract inflammation 8.1%
arthralgia 5.4%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 31.5%
hypoglycaemia 14%
contusion 7%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 6.6% (placebo 3.3%)
hyperglycaemia 2.8% (placebo 9.2%)
NCT01194830 · Phase 3 · registry result, not featured evidence
5 mg
hypoglycaemia 30.3% (placebo 31.3%)
hyperglycaemia 14.3% (placebo 17.8%)
nasopharyngitis 11.3% (placebo 9.8%)
NCT00954447 · Phase 3 · registry result, not featured evidence
linagliptin 2.5 mg bid + metformin 1000 mg bid
diabetes mellitus 9.9%
diarrhoea 7%
nasopharyngitis 7%
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
linagliptin 2.5 mg bid + metformin 500 mg bid
hyperglycaemia 12.9%
diabetes mellitus 8%
glomerular filtration rate decreased 6.2%
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
5 mg
hypoglycaemia 22.8% (placebo 16.5%)
nasopharyngitis 10.5% (placebo 8.9%)
diarrhoea 5.6% (placebo 2.5%)
NCT01084005 · Phase 3 · registry result, not featured evidence
hyperglycaemia 14.6%
nasopharyngitis 9.9%
dizziness 7.3%
NCT00740051 · Phase 3 · registry result, not featured evidence
nasopharyngitis 9.3% (placebo 8.5%)
upper respiratory tract infection 3.5% (placebo 7.7%)
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
hyperglycaemia 8.6% (placebo 22.8%)
NCT00621140 · Phase 3 · registry result, not featured evidence
10 mgi
influenza 15.5% (placebo 15.1%)
nasopharyngitis 15.5% (placebo 14%)
headache 13.3% (placebo 12.3%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
5 mg
influenza 16.2% (placebo 15.1%)
nasopharyngitis 14.7% (placebo 14%)
arthralgia 10.5% (placebo 6.7%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg
diarrhoea 15.1% (placebo 12.8%)
nasopharyngitis 14.6% (placebo 14%)
headache 14.1% (placebo 12.3%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
10 mg
arthralgia 16.3% (placebo 7.4%)
headache 16.3% (placebo 16.8%)
influenza 15.3% (placebo 6.3%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
upper respiratory tract infection 15.1% (placebo 15.8%)
urinary tract infection 13.2% (placebo 8.4%)
headache 12.3% (placebo 16.8%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg
diarrhoea 13.7% (placebo 8.4%)
upper respiratory tract infection 11.8% (placebo 15.8%)
influenza 10.8% (placebo 6.3%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
10mg
nasopharyngitis 9.3%
NCT02471404 · Phase 4 · registry result, not featured evidence
5mg and 10mg
nasopharyngitis 9.9%
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
hyperlipidaemia 6.2%
hyperlipidaemia 3.7%
abdominal distension 1.2%
NCT02243176 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 2.7%
dizziness 2.6%
NCT01608724 · Phase 4 · registry result, not featured evidence
diabetes mellitus 6.5% (placebo 8.1%)
dizziness 4.5% (placebo 4.2%)
hypertension 4.2% (placebo 3.9%)
NCT01107886 · Phase 4 · registry result, not featured evidence
5 mg
nasopharyngitis 6.4%
arthralgia 4.7%
diarrhoea 4.2%
NCT01006603 · Phase 4 · registry result, not featured evidence
hypoglycaemia 6.8%
diarrhoea 6.1%
nasopharyngitis 5.4%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
5 mg
toothache 7.7% (placebo 0%)
acne 3.8% (placebo 0%)
animal bite 3.8% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
5 mg
aphthous ulcer 3.8% (placebo 0%)
back pain 3.8% (placebo 2.6%)
colitis 3.8% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
5 mg
nasopharyngitis 15.4% (placebo 2.6%)
asthma 7.7% (placebo 0%)
covid-19 7.7% (placebo 2.6%)
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
2.5 mg
vitamin d deficiency 4.5% (placebo 6.6%)
nausea 3.4% (placebo 0%)
urinary tract infection 3.4% (placebo 5.3%)
NCT03199053 · Phase 3 · registry result, not featured evidence
2.5 mg
influenza 4.9% (placebo 2.6%)
bronchitis 1.6% (placebo 0%)
chronic sinusitis 1.6% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
2.5 mg
covid-19 6.6% (placebo 2.6%)
upper respiratory tract infection 6.6% (placebo 2.6%)
urinary tract infection 4.9% (placebo 5.3%)
NCT03199053 · Phase 3 · registry result, not featured evidence
dapagliflozin 10 mg, saxagliptin 5 mg
urinary tract infection 13.7%
upper respiratory tract infection 10.1%
headache 7.9%
NCT02419612 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 7.7%
upper respiratory tract infection 5.2%
headache 3.7%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
glomerular filtration rate decreased 4.1%
pollakiuria 2.4%
urinary tract infection 2.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
nasopharyngitis 7.8%
headache 5.6%
urinary tract infection 4.3%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
oropharyngeal pain 50% (placebo 25%)
acne 25% (placebo 0%)
cough 25% (placebo 25%)
NCT01204775 · Phase 3 · registry result, not featured evidence
headache 50% (placebo 0%)
abdominal pain upper 25% (placebo 0%)
back pain 25% (placebo 0%)
NCT01434186 · Phase 3 · registry result, not featured evidence
5 mg QD
hypoglycaemia 21.8% (placebo 23.8%)
upper respiratory tract infection 2.6% (placebo 4.3%)
urinary tract infection 2.6% (placebo 0.9%)
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
urinary tract infection 9.4% (placebo 10%)
influenza 7.5% (placebo 7.5%)
headache 6.9% (placebo 8.1%)
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 7.2% (placebo 6.8%)
headache 5.9% (placebo 7.4%)
nasopharyngitis 5.9% (placebo 4.9%)
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 6.2% (placebo 9.4%)
diarrhoea 5.4% (placebo 3.9%)
hypertension 5.4% (placebo 1.6%)
NCT01128153 · Phase 3 · registry result, not featured evidence
diarrhoea 5.8%
urinary tract infection 5.1%
nasopharyngitis 4.3%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 10.7%
diarrhoea 5.8%
upper respiratory tract infection 5.8%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 8.4% (placebo 9.4%)
NCT00918879 · Phase 3 · registry result, not featured evidence
5 mg + Metformin XR 1500 mg
cough 6.5%
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 7.6% (placebo 7.9%)
nasopharyngitis 6.3% (placebo 6.6%)
upper respiratory tract infection 6.3% (placebo 7.3%)
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
hypoglycaemia 28.2% (placebo 29.4%)
anaemia 5.9% (placebo 8.2%)
hypertension 5.9% (placebo 5.9%)
NCT00614939 · Phase 3 · registry result, not featured evidence
5 mg
headache 25% (placebo 18.8%)
muscle spasms 25% (placebo 0%)
infusion site pain 20% (placebo 12.5%)
NCT00374907 · Phase 3 · registry result, not featured evidence
5 mg
upper respiratory tract infection 6.3% (placebo 7.7%)
NCT00698932 · Phase 3 · registry result, not featured evidence
5 mg
upper respiratory tract infection 6.7% (placebo 4.5%)
NCT00661362 · Phase 3 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTrial phases differ: Phase 4 versus Phase 3.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 24 weeks versus 156 weeks.
  6. fTrial phases differ: Phase 3 versus Phase 4.
  7. gTreatment context differs: monotherapy versus combination.
  8. hPopulation comparability has not been reviewed for 55 of these studies.
  9. iPopulation comparability has not been reviewed for 38 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Linagliptin

HbA1c Less Than 6 5 9.9% (n=115) vs 6.7% (n=120) Glimepiride @ 52wk5 mg
absolute value · percentage points
NCT01087502 · Phase 3 · registry result, not featured evidence
show 9 more results
6.1% (n=115) vs 5% (n=120) Glimepiride @ 12wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
13.1% (n=777) vs 4.2% (n=262) placebo @ 24wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
13.1% (n=778) vs 4.2% (n=262) placebo @ 24wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.4% (n=511) vs 2.3% (n=171) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.7% (n=513) vs 3.4% (n=175) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
17.5% (n=252) vs 14.1% (n=128) placebo @ 24wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
17.5% (n=252) vs 14.1% (n=128) placebo @ 24wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
10.6% (n=329) vs 4.9% (n=162) placebo @ 24wk
NCT00621140 · Phase 3 · registry result, not featured evidence
10.8% (n=333) vs 4.9% (n=163) placebo @ 24wk
NCT00621140 · Phase 3 · registry result, not featured evidence
HbA1c Reduction 0 5 58.2% (n=778) vs 30.2% (n=262) placebo @ 24wk
absolute value · percentage points
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
49.7% (n=513) vs 21.7% (n=175) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
PPG Increment Over FPG mg/dL -1.72 vs 0.61 placebo mmol/L @ 24wk
absolute value · mmol/L
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -30.9 mg/dL as posted
Treatment Failure 50% (n=6) vs 60% (n=5) placebo @ 26wk5 mg
responder rate · % of participants
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time to Treatment Failure 2.37 vs 2.16 placebo months5 mg
time to event · months
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to months from 72.167 days as posted
Seated SBP 2.21 vs 1.3 placebo mmHg @ 26wk5 mg
absolute change · mmHg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
5.16 vs 1.3 placebo mmHg @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
Seated DBP 2.26 vs 0.76 placebo mmHg @ 26wk5 mg
absolute change · mmHg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
6.75 vs 0.76 placebo mmHg @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than 6 5 15.4% (n=52) vs 9.4% (n=53) placebo @ 26wk5 mg
responder rate · % of participants
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 7 more results
16.7% (n=6) vs 9.4% (n=53) placebo @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
23.4% (n=141) vs 34.7% (n=144) Metformin @ 24wk5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
11.8% (n=221) vs 0% (n=43) placebo @ 12wk5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
56.3% (n=142) vs 34.7% (n=144) Metformin @ 24wk2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
60.3% (n=141) vs 34.7% (n=144) Metformin @ 24wk2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
12.7% (n=212) vs 0% (n=43) placebo @ 12wk2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
4% (n=101) vs 3% (n=100) placebo @ 24wk
NCT02897349 · Phase 3 · registry result, not featured evidence
MACE 4-point Composite 23.4% (n=3023) vs 23.7% (n=3010) Glimepiride @ 432wk
event count · % of participants
NCT01243424 · Phase 3
HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain 16% (n=3014) vs 10.2% (n=3000) Glimepiride @ 432wk
absolute value · percentage points
Maintenance
NCT01243424 · Phase 3
HbA1c Less Than 7 Without Weight Gain 17.4% (n=3014) vs 14.1% (n=3000) Glimepiride @ 432wk
absolute value · percentage points
Maintenance
NCT01243424 · Phase 3
MACE 4-point Composite 13.2% (n=3023) vs 13.3% (n=3010) Glimepiride @ 432wk
absolute value · percentage points
NCT01243424 · Phase 3

+ 46 further endpoints in the CSV export.

Saxagliptin

HbA1c -0.58% (n=180) vs 0.13% (n=175) placebo @ 24wk10 mg
absolute change · percentage points
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 8 more results
-0.54% (n=98) vs 0.19% (n=95) placebo @ 24wk10 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.69% (n=186) vs 0.13% (n=175) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.46% (n=106) vs 0.19% (n=95) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.84% (n=277) vs -0.34% (n=274) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-0.59% (n=186) vs 0.13% (n=175) placebo @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.43% (n=102) vs 0.19% (n=95) placebo @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.56% (n=74) vs -0.22% (n=84) placebo @ 12wk2.5 mg
Adjusted Mean Change From Baseline
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
-0.86% (n=81) vs -0.44% (n=83) placebo @ 12wk
Adjusted Mean Change from Baseline
NCT00614939 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose -1.14 vs 0.07 placebo mmol/L @ 24wk10 mg
absolute change · mmol/L
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -20.5 mg/dL as posted
show 6 more results
-1.22 vs 0.07 placebo mmol/L @ 24wk*5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -22.03 mg/dL as posted
-0.9 vs -0.17 placebo mmol/L @ 24wk5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.17 placebo mmol/L @ 24wk*5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.13 mg/dL as posted
-0.79 vs 0.07 placebo mmol/L @ 24wk*2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.31 mg/dL as posted
-0.52 vs -0.2 Metformin mmol/L @ 4wk*5 mg + Metformin XR 1500 mg
Adjusted mean change from baseline
NCT00918138 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -9.3 mg/dL as posted
-0.76 vs -0.23 placebo mmol/L @ 12wk*2.5 mg
Adjusted Mean Change from Baseline
NCT00885378 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -13.73 mg/dL as posted
Postprandial Glucose AUC -8137 vs -3291 placebo mg @ 24wk10 mg
absolute change · mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-9586 vs -3291 placebo mg @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-7534 vs -4255 placebo mg @ 24wk5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-8891 vs -3291 placebo mg @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
Fasting Plasma Glucose -0.93 vs 0.34 placebo mmol/L @ 24wk10 mg
absolute change · mmol/L
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -16.75 mg/dL as posted
show 4 more results
-0.48 vs 0.34 placebo mmol/L @ 24wk*5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -8.67 mg/dL as posted
-1.14 vs -0.58 placebo mmol/L @ 24wk5 mg
Adjusted Change from Baseline
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
-1.14 vs -0.58 placebo mmol/L @ 24wk*5 mg
Adjusted Change from Baseline
NCT00661362 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -20.52 mg/dL as posted
-0.81 vs 0.34 placebo mmol/L @ 24wk*2.5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.53 mg/dL as posted
Postprandial Glucose AUC -8084 vs -646.6 placebo mg @ 24wk10 mg
absolute change · mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 2 more results
-6896 vs -646.6 placebo mg @ 24wk5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-6868 vs -646.6 placebo mg @ 24wk2.5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c 6.8% (n=21) vs 6.6% (n=21) placebo @ 6wk
absolute value · percentage points
Visit 2 - Week 6
NCT02024477 · Phase 4 · registry result, not featured evidence
HbA1c 6.7% (n=21) vs 6.5% (n=21) placebo @ 12wk
absolute value · percentage points
Visit 3 - Week 12
NCT02024477 · Phase 4 · registry result, not featured evidence
Time to Rescue Medication NA vs NA Glimepiride months @ 52wk10mg
time to event · months
NCT02471404 · Phase 4 · registry result, not featured evidence
show 2 more results
NA vs 21.3 Glimepiride months @ 156wkdapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
NA vs NA Glimepiride months @ 52wk5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
Rescue 18.6% (n=311) vs 21.4% (n=309) Glimepiride @ 52wk10mg
responder rate · % of participants
NCT02471404 · Phase 4 · registry result, not featured evidence
show 1 more result
8.3% (n=312) vs 21.4% (n=309) Glimepiride @ 52wk5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without GI AE 37% (n=230) vs 28.8% (n=229) Acarbose @ 24wk
responder rate · % of participants
NCT02243176 · Phase 4 · registry result, not featured evidence
PPG 2H -0.77 vs -1.07 Acarbose mmol/L @ 24wk
absolute change · mmol/L
NCT02243176 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.65 vs 0.28 placebo mmol/L @ 24wk*
NCT01128153 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -11.66 mg/dL as posted
-0.65 vs 0.28 placebo mmol/L @ 24wk
NCT01128153 · Phase 3 · registry result, not featured evidence
HOMA-B 20.56 vs 13.08 Acarbose mU/mmol @ 24wk
absolute change · mU/mmol
NCT02243176 · Phase 4 · registry result, not featured evidence

+ 36 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Linagliptin's landscape · Saxagliptin's landscape